Choroidal Neovascularization - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 84 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Choroidal Neovascularization - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Choroidal Neovascularization - Pipeline Review, H2 2014', provides an overview of the Choroidal Neovascularization's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Choroidal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Choroidal Neovascularization and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Choroidal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Choroidal Neovascularization pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Choroidal Neovascularization Overview 8
Therapeutics Development 9
Pipeline Products for Choroidal Neovascularization - Overview 9
Pipeline Products for Choroidal Neovascularization - Comparative Analysis 10
Choroidal Neovascularization - Therapeutics under Development by Companies 11
Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes 13
Choroidal Neovascularization - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Choroidal Neovascularization - Products under Development by Companies 17
Choroidal Neovascularization - Products under Investigation by Universities/Institutes 18
Choroidal Neovascularization - Companies Involved in Therapeutics Development 19
Affitech A/S 19
F. Hoffmann-La Roche Ltd. 20
Genentech, Inc. 21
MABLife S.A.S 22
Navigen Pharmaceuticals, Inc. 23
Promedior, Inc. 24
Regeneron Pharmaceuticals, Inc. 25
Resolvyx Pharmaceuticals, Inc 26
Sanwa Kagaku Kenkyusho Co., Ltd. 27
Valens Therapeutics, Inc. 28
Choroidal Neovascularization - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
aflibercept (recombinant) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Antisense Oligonucleotides to Inhibit VEGFR-1 and VEGFR-2 for Ophthalmology and Cancer - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drug to Target Netrin-4 for Cancer and Choroidal Neovascularization - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MAb-30D8 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MAT-302 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NAV-2729 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PGN-635 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PRM-167 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ranibizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Recombinant Protein for Choroidal Neovascularization - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
RX-20001 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SK-1011 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules for Ocular Diseases - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit Arf6 for Multiple Diseases - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Choroidal Neovascularization - Recent Pipeline Updates 62
Choroidal Neovascularization - Dormant Projects 75
Choroidal Neovascularization - Discontinued Products 76
Choroidal Neovascularization - Product Development Milestones 77
Featured News & Press Releases 77
Sep 22, 2014: Regeneron Announces EYLEA (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization in Japan 77
Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance 77
Nov 18, 2013: Data at 48 weeks for Phase 3 MYRROR trial in mCNV demonstrate long-term efficacy of VEGF Trap-Eye 78
Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization 79
Jun 06, 2013: Regeneron And Bayer Report Positive Phase III Results For Eylea Injection In Myopic Choroidal Neovascularization 80
May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections 81
Jan 03, 2012: Regeneron Announces Settlement Of Patent Litigation With Genentech For US Ophthalmic Sales Of EYLEA Injection 81
Jan 18, 2011: Regeneron And Bayer Start Phase III Trial To Extend Ophthalmology Research & Development Program For VEGF Trap-Eye In Asia 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables
Number of Products under Development for Choroidal Neovascularization, H2 2014 9
Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Choroidal Neovascularization - Pipeline by Affitech A/S, H2 2014 19
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 20
Choroidal Neovascularization - Pipeline by Genentech, Inc., H2 2014 21
Choroidal Neovascularization - Pipeline by MABLife S.A.S, H2 2014 22
Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 23
Choroidal Neovascularization - Pipeline by Promedior, Inc., H2 2014 24
Choroidal Neovascularization - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 25
Choroidal Neovascularization - Pipeline by Resolvyx Pharmaceuticals, Inc, H2 2014 26
Choroidal Neovascularization - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2014 27
Choroidal Neovascularization - Pipeline by Valens Therapeutics, Inc., H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 33
Number of Products by Stage and Route of Administration, H2 2014 35
Number of Products by Stage and Molecule Type, H2 2014 37
Choroidal Neovascularization Therapeutics - Recent Pipeline Updates, H2 2014 62
Choroidal Neovascularization - Dormant Projects, H2 2014 75
Choroidal Neovascularization - Discontinued Products, H2 2014 76